Brilinta, a new generation anticoagulant, may cause uncontrollable internal bleeding that may prove fatal. Unfortunately, there is currently no available antidote to stop hemorrhaging that sometimes occurs among patients taking the medication.
Bernstein Liebhard LLP is now investigating Brilinta lawsuits on behalf of individuals who may have suffered serious complications allegedly related to its use, including:
If you or a loved one experienced any of these complications while using Brilinta, please call (888) 994-5118 to discuss your case with an attorney at our Firm.
Brilinta was approved by the U.S. Food & Drug Administration (FDA) in 2011, and is now prescribed to lower the risk of stroke or serious heart problems in patients who’ve had angina (severe chest pain) or a previous heart attack. It is also used to prevent these same conditions in patients undergoing certain heart surgeries, including stent placement, coronary artery bypass graft-CABG, or angioplasty.
In 2013, an article that appeared in the International Journal of Cardiology raised concerns that AstraZeneca may have altered clinical trial data to make Brilinta appear safer than it actually is. The clinical trial in question, PLATO, involved 18,000 patients and compared Brilinta to Plavix. Favorable findings from PLATO played a major role in the FDA’s decision to approve Brilinta.
The subsequent review of PLATO found that 6% of all primary endpoint events favoring Brilinta came from just 2 countries, Poland and Hungary, even though patients from around the world participated in the trial. The same review also found that heart attacks were underreported, and suggested that problems with Plavix had been reported more harshly and more frequently compared to those associated with Brilinta.
The U.S. Department of Justice opened an investigation into the PLATO trial shortly after the review appeared in the International Journal of Cardiology. However, the probe ended one year later, with prosecutors taking no action.
In 2015, AstraZeneca released the results of the PEGASUS-TIMI 54 trial, which involved 21,000 patients who had suffered at least one heart attack in the past three years. Patients received aspirin therapy, along with either a high dose of Brilinta, a low dose of Brilinta, or a placebo drug. The findings suggested that patients treated with Brilinta were less likely to die from heart problems, a repeat heart attack, or a stroke. However, they were two times more likely to experience major bleeding event than those in the placebo group.
The attorneys at Bernstein Liebhard LLP would like to hear from anyone who experienced a heart attack, stroke, or uncontrollable bleeding event while using Brilinta. To learn more about pursuing a Brilinta lawsuit on behalf of yourself or a loved one, please call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.